Cocrystal Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of various antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza. It is also involved in identifying and developing various non-nucleoside polymerase inhibitors for norovirus gastroenteritis. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck & Co., Inc. to discover and develop proprietary influenza A/B antiviral agents; and a collaboration agreement National Institute of Health. The company was founded in 2007 and is headquartered in Tucker, Georgia.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [10/17/2019 07:53 PDT] COCP Expected to Trade Up After Bullish Patterns Develop
• [10/16/2019 07:42 PDT] COCP Expected to Trade Up After Bullish Patterns Develop
• [10/09/2019 12:23 PDT] Cocrystal Pharma, Inc. (NASDAQ:COCP), Down By 100.00% ($2.00) From $2.000 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [10/04/2019 08:09 PDT] COCP Expected to Trade Down After Bearish Patterns Develop
• [09/18/2019 11:07 PDT] Cocrystal Pharma, Inc. (NASDAQ:COCP), Up By 100.00% ($1.80) From $1.800 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [09/16/2019 07:56 PDT] COCP Expected to Trade Up After Bullish Patterns Develop
• [09/11/2019 07:44 PDT] COCP Expected to Trade Down After Bearish Patterns Develop
• [09/03/2019 07:58 PDT] COCP Expected to Trade Up After Bullish Patterns Develop
• [08/21/2019 12:42 PDT] Cocrystal Pharma, Inc. (NASDAQ:COCP), Down By 100.00% ($2.56) From $2.560 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions